Clintec, the global service Contract Research Organisation (CRO), is honoured to announce that it has been awarded the Queen’s Award for Enterprise 2017 in the category of International Trade for a second time.
The Queen’s Award, the highest accolade that can be granted to any business operating within the UK, recognises outstanding corporate achievement.
Clintec was selected from amongst some of the top performing UK businesses for its differentiated geographical capability and impressive growth in the mid-market of the contract research sector.
Clintec launched into the clinical research sector 20 years ago and has organically developed a broad, diverse and cohesive geographical footprint spanning over 50 countries with permanent employees.
Powered by the latest technologies in the industry, Clintec provides flexible access to their global platform for clinical trial execution. This value proposition equips their clients with the ability to conduct the most complex of international clinical development programmes without the fixed-cost and oversight burden of utilising their own resources and technology.
Dr. Rabinder Buttar, Founder and CEO of Clintec, said: “We are honoured to have received the Queen’s Award for Enterprise again as we celebrate 20 years of global success in clinical research. The people of Clintec are very excited and energised to grow the business further and continue to deliver excellent clinical research solutions to our clients, several of whom have partnered with us for many years”.
Dr. Buttar added: “The United Kingdom has served as a great base from which we have expanded into over 50 countries and we would like to thank all people in the UK and worldwide who have supported us along our incredible journey".
Clintec’s extensive global reach throughout Western Europe, Central and Eastern Europe, Middle East and North Africa, Sub-Saharan Africa, Asia Pacific and North America, provides access to both developed and emerging markets, and all to the global clinical and ethical standards required for high-quality drug development.
Clintec specialises in clinical research solutions and functional service provision across Phases I-IV in drug development with particular expertise in oncology and rare diseases. The company is developing innovative best-in-class treatments within the immuno-oncology space, to assist patients with various forms of cancer to obtain new and much needed therapies. The company partners with many of the world’s global pharmaceutical companies, as well as smaller biotechnology companies, to fast-track their product development using innovative and flexible outsourcing solutions underpinned with an entrepreneurial and client-centric approach.
The award will be bestowed upon Clintec by Her Majesty The Queen on the advice of the Prime Minister.
Clintec International is a global full service Contract Research Organisation (CRO) with an organically grown presence, including legal entities, in over 50 developed and emerging countries and with operational capabilities in more than 80 countries. Clintec provides innovative full and functional clinical research solutions to 7 of the top 10 pharmaceutical companies in the world, as well as leading biotechnology and medical device firms in oncology, rare diseases and other therapeutic areas. In addition, Clintec provides support to a diverse range of organisations, including not-for-profit organisations, to develop medicines for infectious diseases in countries where significant unmet needs exist. The company excels in conducting Phase I – IV clinical studies, supported by an experienced world-class team of locally based clinical research professionals.
Headquartered in the UK and going into its 20th year of significant global expansion, Clintec’s focused, flexible and forward approach ensures quick and reliable delivery through solutions which are customised to the global clinical research needs of each of its clients.